^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTNNB1 S45P

    i
    Other names: CTNNB1, armadillo, beta-catenin, CTNNB, Catenin (cadherin-associated protein), beta 1
    Entrez ID:
    1499
    Related biomarkers:
    Expression
    Mutation
    Others
    8ms
    A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (clinicaltrials.gov)
    P1/2, N=39, Completed, Gritstone bio, Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2023 | Trial primary completion date: Dec 2023 --> Mar 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • IO biomarker • Checkpoint block • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS Q61R • NRAS G12 • NRAS Q61L • NRAS G13D • CTNNB1 S45P • NRAS G12V • KRAS expression • NRAS G12C
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS
    9ms
    Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma. (PubMed, Front Genet)
    The TP53 R249M mutation was also significantly (p < 0.0001) associated with smoking habits (OR, 11.77; 95% CI, 3.219-36.20), but not the same for the TP53 R249S mutation. Screening of ctDNA TP53 and CTNNB1 gene mutations by ddPCR may be helpful for early detection and identifying the risk of HCC progression.
    Journal • Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    TP53 mutation • CTNNB1 S45P • TP53 G245S
    1year
    A Subset of Pancreatoblastomas May Arise From an Adenomatous Precursor: An Ampullary Pancreatoblastoma and Adjacent Adenoma With a Shared Molecular Phenotype in an Adult Patient. (PubMed, Pancreas)
    In addition, this case is just the second pancreatoblastoma to originate in the duodenal ampulla, and the preceding case suggests that an ampullary location leads to earlier diagnosis. Moreover, this case highlights the difficulty in diagnosing pancreatoblastoma on limited tissue specimens and illustrates the need to include pancreatoblastoma in the differential diagnosis in all tumors in and around the pancreas, including those in adult patients.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    CTNNB1 S45P
    over1year
    A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (clinicaltrials.gov)
    P1/2, N=39, Active, not recruiting, Gritstone bio, Inc. | Recruiting --> Active, not recruiting | N=144 --> 39
    Enrollment closed • Enrollment change • Combination therapy • Checkpoint inhibition • IO biomarker • Checkpoint block • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS Q61R • NRAS G12 • NRAS Q61L • NRAS G13D • CTNNB1 S45P • NRAS G12V • KRAS expression • NRAS G12C
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS
    over1year
    A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Gritstone bio, Inc. | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date • Combination therapy • Checkpoint inhibition • IO biomarker • Checkpoint block • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS Q61R • NRAS G12 • NRAS Q61L • NRAS G13D • CTNNB1 S45P • NRAS G12V • KRAS expression • NRAS G12C
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS